Clinical applications for co-ed bioFFR inhibitors were accepted.

LianBio submitted a clinical trial application for the FGFR inhibitor infigratinib capsule in China, which was accepted on August 26, according to the latest announcement from the Drug Review Center (CDE) of the State Drug Administration of China.
it is worth noting that Otto Bio was officially inaugurated on 11 August, just 15 days after its first IND was accepted.
: CDE.com The company has reached strategic partnerships with BridgeBio Pharma and MyoKardia, respectively, amounting to hundreds of millions of dollars.
, the company's pipeline includes a variety of potentially breakthrough therapeutic products from Myokardia, as well as BridgeBio Pharma subsidiaries Navire Pharma and QED Therapeutics.
strategic partnership with BridgeBio Pharma gives Interalife priority access to more than 20 of its pipeline products.
infigratinib capsule, which is currently clinically declared, is one of the key products in the early stages of our partnership with BridgeBio.
Infigratinib is a selective FGFR inhibitor currently in phase 3 development for the treatment of diseases such as bile tube cancer (CCA) and urethra (bladder cancer) caused by abnormal FGFR genes.
As part of QED PROOF's Global Phase 3 clinical study, UTO Bio is conducting Chinese mainland research on the use of infigratinib in the treatment of first-line bile tube cancer, and further plans to initiate phase 2a clinical studies of infigratinib for gastric cancer and other tumor diseases caused by mutations in the FGFR gene.
in the research pipeline (screenshot source: Umto Bio-official website) Reference: 1. China's State Drug Administration Drug Review Center (CDE). Retrieved Aug 27, 2020, from .4. From.